New drugs for HIV and hepatitis C virus infections: A report from CROI 2011

Research output: Contribution to journalArticle

Abstract

Presentations on new therapies for hepatitis C virus (HCV) generated the most excitement at CROI 2011. Two new, orally available, direct-acting antivirals, boceprevir and telaprevir, promise to usher in a new era of combination therapy for chronic HCV infection. The antiretroviral drug development pipeline continues to expand, albeit at a slower pace than in recent years.

Original languageEnglish (US)
Pages (from-to)485-490
Number of pages6
JournalDrugs of the Future
Volume36
Issue number6
DOIs
StatePublished - 2011

Fingerprint

Virus Diseases
Hepacivirus
HIV
Chronic Hepatitis C
Pharmaceutical Preparations
Antiviral Agents
Therapeutics
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
telaprevir

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

New drugs for HIV and hepatitis C virus infections : A report from CROI 2011. / Temesgen, Zelalem.

In: Drugs of the Future, Vol. 36, No. 6, 2011, p. 485-490.

Research output: Contribution to journalArticle

@article{5e3fa754043c498c99a91727702de4b2,
title = "New drugs for HIV and hepatitis C virus infections: A report from CROI 2011",
abstract = "Presentations on new therapies for hepatitis C virus (HCV) generated the most excitement at CROI 2011. Two new, orally available, direct-acting antivirals, boceprevir and telaprevir, promise to usher in a new era of combination therapy for chronic HCV infection. The antiretroviral drug development pipeline continues to expand, albeit at a slower pace than in recent years.",
author = "Zelalem Temesgen",
year = "2011",
doi = "10.1358/dof.2011.036.06.1617338",
language = "English (US)",
volume = "36",
pages = "485--490",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "6",

}

TY - JOUR

T1 - New drugs for HIV and hepatitis C virus infections

T2 - A report from CROI 2011

AU - Temesgen, Zelalem

PY - 2011

Y1 - 2011

N2 - Presentations on new therapies for hepatitis C virus (HCV) generated the most excitement at CROI 2011. Two new, orally available, direct-acting antivirals, boceprevir and telaprevir, promise to usher in a new era of combination therapy for chronic HCV infection. The antiretroviral drug development pipeline continues to expand, albeit at a slower pace than in recent years.

AB - Presentations on new therapies for hepatitis C virus (HCV) generated the most excitement at CROI 2011. Two new, orally available, direct-acting antivirals, boceprevir and telaprevir, promise to usher in a new era of combination therapy for chronic HCV infection. The antiretroviral drug development pipeline continues to expand, albeit at a slower pace than in recent years.

UR - http://www.scopus.com/inward/record.url?scp=84952989810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952989810&partnerID=8YFLogxK

U2 - 10.1358/dof.2011.036.06.1617338

DO - 10.1358/dof.2011.036.06.1617338

M3 - Article

AN - SCOPUS:84952989810

VL - 36

SP - 485

EP - 490

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 6

ER -